Cover Image
市場調查報告書

食道癌:開發中產品分析

Esophageal Cancer - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 229727
出版日期 內容資訊 英文 429 Pages
訂單完成後即時交付
價格
Back to Top
食道癌:開發中產品分析 Esophageal Cancer - Pipeline Review, H2 2016
出版日期: 2016年09月21日 內容資訊: 英文 429 Pages
簡介

食道癌是食道發病的癌症之一。主要的症狀有咳嗽和吞嚥障礙,胸部疼痛,壓迫感或加熱感,體重減少等。

本報告提供全球各國治療食道癌所用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

簡介

  • 調查範圍

食道癌概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

食道癌:企業開發中的治療藥

食道癌:大學/機關研究中的治療藥

食道癌:開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

食道癌:企業開發中的產品

食道癌:大學/機關研究中的產品

食道癌的治療藥的開發企業

  • Adaptimmune Therapeutics Plc
  • Advantagene, Inc.
  • Advaxis, Inc.
  • Advenchen Laboratories, LLC
  • Almac Discovery Limited
  • Amgen Inc.
  • ArQule, Inc.
  • Array BioPharma Inc.
  • Aslan Pharmaceuticals Pte. Ltd.
  • ATLAB Pharma SAS
  • Bayer AG
  • Betta Pharmaceuticals Co. Ltd.
  • Boehringer Ingelheim GmbH
  • Celgene Corporation
  • Celldex Therapeutics, Inc.
  • Cellectar Biosciences, Inc.
  • Cerulean Pharma, Inc.
  • Cyclacel Pharmaceuticals, Inc.
  • Genmab A/S
  • Glycotope GmbH
  • Hutchison MediPharma Limited
  • Ignyta, Inc.
  • ImmunoFrontier, Inc.
  • ImmunoGen, Inc.
  • Immunomedics, Inc.
  • Johnson & Johnson
  • Karyopharm Therapeutics, Inc.
  • Komipharm International Co., Ltd.
  • MacroGenics, Inc.
  • Mebiopharm Co., Ltd.
  • MedImmune, LLC
  • Merck & Co., Inc.
  • Novartis AG
  • Omeros Corporation
  • Omnitura Therapeutics Inc.
  • Oncolys BioPharma Inc.
  • 小野藥品工業
  • Pfizer Inc.
  • Proteo, Inc.
  • Puma Biotechnology, Inc.
  • Shenzen SiBiono GeneTech Co., Ltd.
  • 鹽野義製藥
  • Sihuan Pharmaceutical Holdings Group Ltd.
  • Spectrum Pharmaceuticals, Inc.
  • Symphogen A/S
  • Synta Pharmaceuticals Corp.
  • 大鵬藥品工業
  • Taiwan Liposome Company, Ltd.
  • TaKaRa BIO
  • tella Inc
  • TG Therapeutics, Inc.
  • Transgene Biotek Limited
  • VioQuest Pharmaceuticals, Inc.
  • Virocan Therapeutics Private Limited

食道癌:治療藥的評估

  • 單劑產品
  • 組合產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

食道癌:最近的開發平台趨勢

食道癌:暫停中的計劃

食道癌:開發中止的產品

食道癌:產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8465IDB

Summary

Global Markets Direct's, 'Esophageal Cancer - Pipeline Review, H2 2016', provides an overview of the Esophageal Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Esophageal Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Esophageal Cancer and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Esophageal Cancer
  • The report reviews pipeline therapeutics for Esophageal Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Esophageal Cancer therapeutics and enlists all their major and minor projects
  • The report assesses Esophageal Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Esophageal Cancer

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Esophageal Cancer
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Esophageal Cancer pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Esophageal Cancer Overview
  • Therapeutics Development
    • Pipeline Products for Esophageal Cancer - Overview
    • Pipeline Products for Esophageal Cancer - Comparative Analysis
  • Esophageal Cancer - Therapeutics under Development by Companies
  • Esophageal Cancer - Therapeutics under Investigation by Universities/Institutes
  • Esophageal Cancer - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Esophageal Cancer - Products under Development by Companies
  • Esophageal Cancer - Products under Investigation by Universities/Institutes
  • Esophageal Cancer - Companies Involved in Therapeutics Development
    • Adaptimmune Therapeutics Plc
    • Advaxis, Inc.
    • Advenchen Laboratories, LLC
    • Almac Discovery Limited
    • Amgen Inc.
    • ArQule, Inc.
    • Array BioPharma Inc.
    • Aslan Pharmaceuticals Pte. Ltd.
    • ATLAB Pharma SAS
    • Bayer AG
    • Betta Pharmaceuticals Co. Ltd.
    • Boehringer Ingelheim GmbH
    • Celgene Corporation
    • Celldex Therapeutics, Inc.
    • Cellectar Biosciences, Inc.
    • Cerulean Pharma, Inc.
    • Cyclacel Pharmaceuticals, Inc.
    • F. Hoffmann-La Roche Ltd.
    • Genmab A/S
    • GlaxoSmithKline Plc
    • Glycotope GmbH
    • Hutchison MediPharma Limited
    • Ignyta, Inc.
    • ImmunoFrontier, Inc.
    • Immunomedics, Inc.
    • Johnson & Johnson
    • Komipharm International Co., Ltd.
    • MacroGenics, Inc.
    • MaxiVAX SA
    • Mebiopharm Co., Ltd.
    • MedImmune, LLC
    • Merck & Co., Inc.
    • Mirna Therapeutics, Inc.
    • Novartis AG
    • Omeros Corporation
    • Omnitura Therapeutics Inc.
    • Oncolys BioPharma Inc
    • OncoMed Pharmaceuticals, Inc.
    • Ono Pharmaceutical Co., Ltd.
    • Pfizer Inc.
    • Proteo, Inc.
    • Puma Biotechnology, Inc.
    • Rhizen Pharmaceuticals S.A.
    • Shionogi & Co., Ltd.
    • Spectrum Pharmaceuticals, Inc.
    • Symphogen A/S
    • Taiho Pharmaceutical Co., Ltd.
    • Taiwan Liposome Company, Ltd.
    • Takara Bio Inc.
    • Transgene Biotek Limited
    • VioQuest Pharmaceuticals, Inc.
    • XuanZhu Pharma Co., Ltd.
  • Esophageal Cancer - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (tipiracil hydrochloride + trifluridine) - Drug Profile
    • 1-BB1 - Drug Profile
    • ADXS-HER2 - Drug Profile
    • afatinib dimaleate - Drug Profile
    • AL-3818 - Drug Profile
    • ALM-301 - Drug Profile
    • alpelisib - Drug Profile
    • AMG-337 - Drug Profile
    • apatinib - Drug Profile
    • atezolizumab - Drug Profile
    • ATL-101 - Drug Profile
    • binimetinib - Drug Profile
    • brontictuzumab - Drug Profile
    • CDX-1401 - Drug Profile
    • Cellular Immunotherapy for Oncology - Drug Profile
    • Cellular Immunotherapy for Oncology - Drug Profile
    • Cellular Immunotherapy to Target CD-3 and HER-2 for Oncology - Drug Profile
    • Cellular Immunotherapy to Target NY-ESO-1 for Oncology - Drug Profile
    • cetuximab biobetter - Drug Profile
    • CGX-1321 - Drug Profile
    • CRLX-101 - Drug Profile
    • CYC-140 - Drug Profile
    • DKN-01 - Drug Profile
    • donafenib - Drug Profile
    • durvalumab - Drug Profile
    • elgemtumab - Drug Profile
    • erdafitinib - Drug Profile
    • futuximab - Drug Profile
    • ganetespib - Drug Profile
    • gedatolisib - Drug Profile
    • GSK-2256098 - Drug Profile
    • GSK-3377794 - Drug Profile
    • HMPL-309 - Drug Profile
    • I131-CLR1404 - Drug Profile
    • icotinib hydrochloride - Drug Profile
    • IMF-001 - Drug Profile
    • JS-001 - Drug Profile
    • KML-001 - Drug Profile
    • margetuximab - Drug Profile
    • MBP-426 - Drug Profile
    • miR-215 - Drug Profile
    • MMD-37K - Drug Profile
    • Monoclonal Antibodies to Inhibit PD-L2 for Esophageal Cancer - Drug Profile
    • MVXONCO-1 - Drug Profile
    • neratinib - Drug Profile
    • nimotuzumab - Drug Profile
    • nintedanib - Drug Profile
    • nivolumab - Drug Profile
    • OBP-301 - Drug Profile
    • OMN-54 - Drug Profile
    • paclitaxel albumin bound - Drug Profile
    • panitumumab - Drug Profile
    • pasireotide ER - Drug Profile
    • PCA-062 - Drug Profile
    • pembrolizumab - Drug Profile
    • pralatrexate - Drug Profile
    • RXDX-106 - Drug Profile
    • S-222611 - Drug Profile
    • S-588410 - Drug Profile
    • sacituzumab - Drug Profile
    • SDS-eCAR - Drug Profile
    • sirotinib - Drug Profile
    • Small Molecule to Target LGR5 for Esophageal Adenocarcinoma - Drug Profile
    • Small Molecules to Inhibit Histone Demethylase for Esophageal Cancer - Drug Profile
    • SMYD-2BAY02 - Drug Profile
    • TBI-1201 - Drug Profile
    • TBL-0805E - Drug Profile
    • TGR-1202 - Drug Profile
    • tiprelestat - Drug Profile
    • tisotumab vedotin - Drug Profile
    • tivantinib - Drug Profile
    • TLC-388 - Drug Profile
    • triciribine phosphate - Drug Profile
    • Vaccine for Esophageal Cancer and Colorectal Cancer - Drug Profile
    • varlitinib - Drug Profile
    • YQ-23 - Drug Profile
  • Esophageal Cancer - Dormant Projects
  • Esophageal Cancer - Discontinued Products
  • Esophageal Cancer - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Esophageal Cancer, H2 2016
  • Number of Products under Development for Esophageal Cancer - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Development by Companies, H2 2016 (Contd..1)
  • Number of Products under Development by Companies, H2 2016 (Contd..2)
  • Number of Products under Development by Companies, H2 2016 (Contd..3)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Development by Companies, H2 2016 (Contd..2)
  • Products under Development by Companies, H2 2016 (Contd..3)
  • Products under Development by Companies, H2 2016 (Contd..4)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Esophageal Cancer - Pipeline by Adaptimmune Therapeutics Plc, H2 2016
  • Esophageal Cancer - Pipeline by Advaxis, Inc., H2 2016
  • Esophageal Cancer - Pipeline by Advenchen Laboratories, LLC, H2 2016
  • Esophageal Cancer - Pipeline by Almac Discovery Limited, H2 2016
  • Esophageal Cancer - Pipeline by Amgen Inc., H2 2016
  • Esophageal Cancer - Pipeline by ArQule, Inc., H2 2016
  • Esophageal Cancer - Pipeline by Array BioPharma Inc., H2 2016
  • Esophageal Cancer - Pipeline by Aslan Pharmaceuticals Pte. Ltd., H2 2016
  • Esophageal Cancer - Pipeline by ATLAB Pharma SAS, H2 2016
  • Esophageal Cancer - Pipeline by Bayer AG, H2 2016
  • Esophageal Cancer - Pipeline by Betta Pharmaceuticals Co. Ltd., H2 2016
  • Esophageal Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2016
  • Esophageal Cancer - Pipeline by Celgene Corporation, H2 2016
  • Esophageal Cancer - Pipeline by Celldex Therapeutics, Inc., H2 2016
  • Esophageal Cancer - Pipeline by Cellectar Biosciences, Inc., H2 2016
  • Esophageal Cancer - Pipeline by Cerulean Pharma, Inc., H2 2016
  • Esophageal Cancer - Pipeline by Cyclacel Pharmaceuticals, Inc., H2 2016
  • Esophageal Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016
  • Esophageal Cancer - Pipeline by Genmab A/S, H2 2016
  • Esophageal Cancer - Pipeline by GlaxoSmithKline Plc, H2 2016
  • Esophageal Cancer - Pipeline by Glycotope GmbH, H2 2016
  • Esophageal Cancer - Pipeline by Hutchison MediPharma Limited, H2 2016
  • Esophageal Cancer - Pipeline by Ignyta, Inc., H2 2016
  • Esophageal Cancer - Pipeline by ImmunoFrontier, Inc., H2 2016
  • Esophageal Cancer - Pipeline by Immunomedics, Inc., H2 2016
  • Esophageal Cancer - Pipeline by Johnson & Johnson, H2 2016
  • Esophageal Cancer - Pipeline by Komipharm International Co., Ltd., H2 2016
  • Esophageal Cancer - Pipeline by MacroGenics, Inc., H2 2016
  • Esophageal Cancer - Pipeline by MaxiVAX SA, H2 2016
  • Esophageal Cancer - Pipeline by Mebiopharm Co., Ltd., H2 2016
  • Esophageal Cancer - Pipeline by MedImmune, LLC, H2 2016
  • Esophageal Cancer - Pipeline by Merck & Co., Inc., H2 2016
  • Esophageal Cancer - Pipeline by Mirna Therapeutics, Inc., H2 2016
  • Esophageal Cancer - Pipeline by Novartis AG, H2 2016
  • Esophageal Cancer - Pipeline by Omeros Corporation, H2 2016
  • Esophageal Cancer - Pipeline by Omnitura Therapeutics Inc., H2 2016
  • Esophageal Cancer - Pipeline by Oncolys BioPharma Inc, H2 2016
  • Esophageal Cancer - Pipeline by OncoMed Pharmaceuticals, Inc., H2 2016
  • Esophageal Cancer - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2016
  • Esophageal Cancer - Pipeline by Pfizer Inc., H2 2016
  • Esophageal Cancer - Pipeline by Proteo, Inc., H2 2016
  • Esophageal Cancer - Pipeline by Puma Biotechnology, Inc., H2 2016
  • Esophageal Cancer - Pipeline by Rhizen Pharmaceuticals S.A., H2 2016
  • Esophageal Cancer - Pipeline by Shionogi & Co., Ltd., H2 2016
  • Esophageal Cancer - Pipeline by Spectrum Pharmaceuticals, Inc., H2 2016
  • Esophageal Cancer - Pipeline by Symphogen A/S, H2 2016
  • Esophageal Cancer - Pipeline by Taiho Pharmaceutical Co., Ltd., H2 2016
  • Esophageal Cancer - Pipeline by Taiwan Liposome Company, Ltd., H2 2016
  • Esophageal Cancer - Pipeline by Takara Bio Inc., H2 2016
  • Esophageal Cancer - Pipeline by Transgene Biotek Limited, H2 2016
  • Esophageal Cancer - Pipeline by VioQuest Pharmaceuticals, Inc., H2 2016
  • Esophageal Cancer - Pipeline by XuanZhu Pharma Co., Ltd., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Esophageal Cancer - Dormant Projects, H2 2016
  • Esophageal Cancer - Dormant Projects (Contd..1), H2 2016
  • Esophageal Cancer - Dormant Projects (Contd..2), H2 2016
  • Esophageal Cancer - Dormant Projects (Contd..3), H2 2016
  • Esophageal Cancer - Dormant Projects (Contd..4), H2 2016
  • Esophageal Cancer - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Esophageal Cancer, H2 2016
  • Number of Products under Development for Esophageal Cancer - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Top 10 Routes of Administration, H2 2016
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2016
  • Number of Products by Top 10 Molecule Types, H2 2016
  • Number of Products by Stage and Top 10 Molecule Types, H2 2016
Back to Top